| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 13 Nov 2026 | Form 4 |
| 12 Nov 2026 |
Form 4: Feider Stephen, Chief Financial Officer
Received 744 shares by exercise or conversion ($3.79K) · Sold 744 shares ($12.6K) |
| 12 Nov 2026 | 144 |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 |
Form 4: Feider Stephen, Chief Financial Officer
Received 382 shares by exercise or conversion ($1.95K) · Sold 382 shares ($6.51K) |
| 05 Nov 2026 | 144 |
| 04 Nov 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 370 shares ($6.25K) |
| 29 Oct 2026 |
Form 4: Mensinger Mike, Chief Product Officer
Sold 2,650 shares ($58.3K) |
| 28 Oct 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 821 shares ($16.4K) |
| 27 Oct 2026 | 10-Q |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 3... |
| 16 Oct 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 775 shares ($13.4K) |
| 07 Oct 2026 | SCHEDULE 13G |
| 05 Oct 2026 |
Form 4: Hopman Mark, Chief Commercial Officer
Sold 370 shares ($7.02K) |
| 01 Oct 2026 | 144 |
| 23 Sep 2026 |
Form 4: Jones Christy, Director
Sold 6,430 shares ($148K) |
| 22 Sep 2026 | 144 |
| 18 Sep 2026 |
Form 4/A: Hopman Mark, Chief Commercial Officer
Sold 35,994 shares ($665K) |
Loading...